These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26444353)

  • 81. Worse renal outcome of subclass IV-G lupus nephritis patients over IV-S.
    Duque de Sá Carneiro Filho EJ; Jorge LB; Testagrossa L; Bitencourt C; Yu L; Woronik V
    Lupus; 2018 Apr; 27(4):584-590. PubMed ID: 28927317
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus Nephritis Remission Induction: A Historical Head-to-Head Comparative Study.
    Goswami RP; Sircar G; Sit H; Ghosh A; Ghosh P
    J Clin Rheumatol; 2019 Jan; 25(1):28-35. PubMed ID: 29561474
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Recurrent lupus nephritis after transplantation: Clinicopathological evaluation with protocol biopsies.
    Çeltİk A; Şen S; Tamer AF; Yılmaz M; Sarsık B; Özkahya M; Başçı A; Töz H
    Nephrology (Carlton); 2016 Jul; 21(7):601-7. PubMed ID: 26482014
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effects of concomitant hepatitis C virus infection in patients with underlying lupus nephritis on long-term renal outcome.
    Mitwalli AH; Hayat A; Alwakeel J; Hammad D
    Nephrol Dial Transplant; 2012 Feb; 27(2):627-32. PubMed ID: 21771749
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Clinical characteristics of children with membranous lupus nephritis: the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.
    Boneparth A; Wenderfer SE; Moorthy LN; Radhakrishna SM; Sagcal-Gironella AC; von Scheven E;
    Lupus; 2017 Mar; 26(3):299-306. PubMed ID: 27510603
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis.
    Ding H; Kharboutli M; Saxena R; Wu T
    Clin Exp Immunol; 2016 Apr; 184(1):11-8. PubMed ID: 26616478
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Rituximab in Treatment of Children with Refractory Vasculitis and Systemic Lupus Erythematosus - Single Center Experience in Croatia.
    Sršen S; Frković M; Malčić I; Jelušić M
    Acta Dermatovenerol Croat; 2020 Aug; 28(2):63-69. PubMed ID: 32876030
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Mast cells in the kidney biopsies of pediatric patients with lupus nephritis.
    Santos SS; Ramos CM; Monteiro MLGR; Machado JR; Reis MA; Corrêa RRM; Rocha LP
    J Bras Nefrol; 2020 Mar; 42(1):59-66. PubMed ID: 32023339
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The Inflammatory and Oxidative Status of Newly Diagnosed Class III and Class IV Lupus Nephritis, with Six-Month Follow-Up.
    Cerrillos-Gutiérrez JI; Medina-Pérez M; Andrade-Sierra J; De Alba-Razo A; Pacheco-Moisés FP; Cardona-Muñoz EG; Campos-Pérez W; Martínez-López E; Sánchez-Lozano DI; García-Sánchez A; Campos-Bayardo TI; Miranda-Díaz AG
    Antioxidants (Basel); 2023 Dec; 12(12):. PubMed ID: 38136185
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Evaluation of activity, chronicity and tubulointerstitial indices for childhood lupus nephritis.
    Zappitelli M; Duffy CM; Bernard C; Gupta IR
    Pediatr Nephrol; 2008 Jan; 23(1):83-91. PubMed ID: 17957388
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan.
    Tanaka Y; Nakayamada S; Yamaoka K; Ohmura K; Yasuda S
    Mod Rheumatol; 2023 Jan; 33(1):145-153. PubMed ID: 35165714
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Occurrence and localization of FOXP3 + cells in kidney biopsies in lupus nephritis and ANCA-associated vasculitis.
    Zickert A; Janković MR; Malmström V; Chemin K; Gunnarsson I
    Clin Rheumatol; 2023 Oct; 42(10):2889-2895. PubMed ID: 37368057
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Renal Fibrosis in Lupus Nephritis.
    Sciascia S; Cozzi M; Barinotti A; Radin M; Cecchi I; Fenoglio R; Mancardi D; Wilson Jones G; Rossi D; Roccatello D
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430794
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Analysis of HLA-G expression in renal tissue in lupus nephritis: a pilot study.
    Foschi V; Bortolotti D; Doyle AF; Stratigou V; Stephens L; Trivedi P; Rinaldi R; Padovan M; Bortoluzzi A; Lightstone L; Cairns TD; Botto M; Cook TH; Rizzo R; Govoni M; Pickering MC
    Lupus; 2019 Aug; 28(9):1091-1100. PubMed ID: 31291846
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Can we manage lupus nephritis without chronic corticosteroids administration?
    Lightstone L; Doria A; Wilson H; Ward FL; Larosa M; Bargman JM
    Autoimmun Rev; 2018 Jan; 17(1):4-10. PubMed ID: 29108828
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine.
    Lee JS; Oh JS; Kim YG; Lee CK; Yoo B; Hong S
    Lupus; 2020 Jan; 29(1):52-57. PubMed ID: 31793379
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Peripheral Eosinophil Count Associated with Disease Activity and Clinical Outcomes in Hospitalized Patients with Lupus Nephritis.
    Liu R; Peng Y; Ye H; Xia X; Chen W; Huang F; Li Z; Yang X
    Nephron; 2023; 147(7):408-416. PubMed ID: 36657400
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Revisited Cyclophosphamide in the Treatment of Lupus Nephritis.
    Quan XY; Chen HT; Liang SQ; Yang C; Yao CW; Xu YZ; Liu HF; An N
    Biomed Res Int; 2022; 2022():8345737. PubMed ID: 35707391
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy.
    Zhang FS; Nie YK; Jin XM; Yu HM; Li YN; Sun Y
    Rheumatol Int; 2009 Sep; 29(11):1331-5. PubMed ID: 19169882
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis.
    Izmirly PM; Barisoni L; Buyon JP; Kim MY; Rivera TL; Schwartzman JS; Weisstuch JM; Liu DT; Bernstein S; Tseng CE; Belmont HM; Esmon CT; Merrill JT; Askanase AD; Thomas DB; Clancy RM
    Rheumatology (Oxford); 2009 May; 48(5):513-9. PubMed ID: 19286697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.